Skip to main content

Early Detection Research Network (EDRN)

Visit the EDRN Website

The Early Detection Research Network (EDRN) is a collaborative program that maintains comprehensive infrastructure and resources critical to the discovery, development and validation of biomarkers for cancer risk and early detection.

The DCP Cancer Biomarkers Research Group administers this program.

On This Page

All Heading 2s will automatically be pulled in to this list.
Do not edit the content on this template.

About EDRN

The program comprises a public/private sector consortium to accelerate the development of biomarkers that can improve medical practice, ensure data reproducibility and integrity, and adapt to the changing landscape of biomarker science.

Visit the EDRN Website

Grantee Details

PI Name Sort descending	PI Organization	Title	Grant Number	Program Official
Shah, Sohrab P	Sloan-Kettering Inst Can Research United States	Exploiting markers of genomic instability in high-risk pre-invasive ovarian cancer	5R01CA281928-03	Christos Patriotis, Ph.D., M.Sc.
Shain, Alan Hunter	University Of California, San Francisco United States	Pre-cancer atlas of skin cancer	4U01CA294536-02	Nicholas Hodges, Ph.D.
Shalon, Tidhar Dari	Envivo Bio Inc United States	Development and clinical evaluation of the CapScan gastrointestinal sampling device for metabolomics monitoring	5R33CA260665-04	Amit Kumar, Ph.D.
Shelby, Rebecca A	Duke University United States	Persistent Post-Mastectomy Pain: Randomized Clinical Trial of Targeted Pain Coping Skills Training (Targeted-PCST) with Mediational Analysis	5R01CA249959-05	Brennan Streck, Ph.D., RN, M.P.H.
Shelby, Rebecca A	Duke University United States	Persistent Post-Mastectomy Pain: Randomized Clinical Trial of Targeted Pain Coping Skills Training (Targeted-PCST) with Mediational Analysis	5R01CA249959-05	Brennan Streck, Ph.D., RN, M.P.H.
Shelby, Rebecca A	Duke University United States	Improving outcomes for women experiencing premature or early menopause after cancer: development and pilot testing of a novel intervention	1R21CA301298-01	Goli Samimi, Ph.D., M.P.H.
Shelby, Rebecca A	Duke University United States	Improving outcomes for women experiencing premature or early menopause after cancer: development and pilot testing of a novel intervention	1R21CA301298-01	Goli Samimi, Ph.D., M.P.H.
Shiozawa, Yusuke	Wake Forest University Health Sciences United States	Contribution of cutaneous neuro-immune interactions to chemotherapy-induced peripheral neuropathy	1R21CA297068-01	Rachel Altshuler, Ph.D.
Shiozawa, Yusuke	Wake Forest University Health Sciences United States	Contribution of cutaneous neuro-immune interactions to chemotherapy-induced peripheral neuropathy	1R21CA297068-01	Rachel Altshuler, Ph.D.
Shirwan, Haval	University Of Missouri-Columbia United States	Developing a novel agonist of CD137 for cancer immunoprevention	5UG3CA290305-02	Altaf Mohammed, Ph.D.
Shu, Xiao-Ou	Vanderbilt University Medical Center United States	Use of Circulating MicroRNAs for Early Detection and Risk Assessment for Pancreatic Cancer	5R01CA227133-05	Matthew Young, Ph.D.
Shureiqi, Imad	University Of Michigan At Ann Arbor United States	ALOX15 regulation of colon cancer invasiveness via PI3P-linoleic acid metabolism	5R01CA266223-04	Nancy J. Emenaker, Ph.D., RDN, LD, FAND
Siddique, Shahzad	Commonspirit Health Research Institute United States	CIRI Oncology Research Alliance	3UG1CA189809-11S1	Vanessa A. White, M.P.H.
Siddique, Shahzad	Commonspirit Health Research Institute United States	CIRI Oncology Research Alliance	3UG1CA189809-11S1	Vanessa A. White, M.P.H.
Sidransky, David	Johns Hopkins University United States	Racial differences in Immunogenetic Tumorigenesis of Head and Neck Squamous Cell Carcinoma	5R01CA265975-04	Wendy Wang, Ph.D., M.Sc.

News and Events